Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Peptic Ulcer

Free Subscription Articles published in Aliment Pharmacol Ther Retrieve available abstracts of 85 articles: HTML format Text format

Single Articles

August 2019
1. ARGUETA EA, Moss SF
   Editorial: not yet time for universal susceptibility-guided first-line Helicobacter pylori treatment.
   Aliment Pharmacol Ther. 2019;50:331-332.
   PubMed     Text format    
   
   
   
2. LU H, Graham DY
   Editorial: not yet time for universal susceptibility-guided first-line Helicobacter pylori treatment-authors' reply.
   Aliment Pharmacol Ther. 2019;50:332.
   PubMed     Text format    
   
   
   June 2019
3. TEPLER A, Narula N, Peek RM Jr, Patel A, et al
   Systematic review with meta-analysis: association between Helicobacter pylori CagA seropositivity and odds of inflammatory bowel disease.
   Aliment Pharmacol Ther. 2019 Jun 5. doi: 10.1111/apt.15306.
   PubMed     Text format     Abstract available
   
   
   
4. HOLMBERG D, Santoni G, Xie S, Lagergren J, et al
   Gastric bypass surgery in the treatment of gastro-oesophageal reflux symptoms.
   Aliment Pharmacol Ther. 2019 Jun 4. doi: 10.1111/apt.15274.
   PubMed     Text format     Abstract available
   
   
   May 2019
5. RONKAINEN J, Aro P, Walker MM, Agreus L, et al
   Duodenal eosinophilia is associated with functional dyspepsia and new onset gastro-oesophageal reflux disease.
   Aliment Pharmacol Ther. 2019 May 20. doi: 10.1111/apt.15308.
   PubMed     Text format     Abstract available
   
   
   
6. CORFE BM, Chowdry J, Russell JM, Race C, et al
   Letter: studies of salivary pepsin in patients with gastro-oesophageal reflux disease. Authors' reply.
   Aliment Pharmacol Ther. 2019;49:1249-1250.
   PubMed     Text format    
   
   
   
7. RACE C, Chowdry J, Russell JM, Corfe BM, et al
   Studies of salivary pepsin in patients with gastro-oesophageal reflux disease.
   Aliment Pharmacol Ther. 2019;49:1173-1180.
   PubMed     Text format     Abstract available
   
   
   
8. DETTMAR PW, Woodcock AD, Wilcox MD, Chater PI, et al
   Letter: studies of salivary pepsin in patients with gastro-oesophageal reflux disease.
   Aliment Pharmacol Ther. 2019;49:1248-1249.
   PubMed     Text format    
   
   
   
9. HOGH MB, Kronborg C, Moller Hansen J, Wildner-Christensen M, et al
   Editorial: population-based testing for Helicobacter pylori in Western countries. Authors' reply.
   Aliment Pharmacol Ther. 2019;49:1361.
   PubMed     Text format    
   
   
   
10. VAKIL N
    Editorial: population-based testing for Helicobacter pylori in Western countries.
    Aliment Pharmacol Ther. 2019;49:1360.
    PubMed     Text format    
    
    
    April 2019
11. CHEN Q, Long X, Ji Y, Liang X, et al
    Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment.
    Aliment Pharmacol Ther. 2019 Apr 24. doi: 10.1111/apt.15273.
    PubMed     Text format     Abstract available
    
    
    March 2019
12. HOGH MB, Kronborg C, Hansen JM, Schaffalitzky de Muckadell OB, et al
    The cost effectiveness of Helicobacter pylori population screening-economic evaluation alongside a randomised controlled trial with 13-year follow-up.
    Aliment Pharmacol Ther. 2019 Mar 10. doi: 10.1111/apt.15193.
    PubMed     Text format     Abstract available
    
    
    
13. LEE KJ, Son BK, Kim GH, Jung HK, et al
    Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis.
    Aliment Pharmacol Ther. 2019 Mar 6. doi: 10.1111/apt.15185.
    PubMed     Text format     Abstract available
    
    
    
14. YUAN Y, Leontiadis GI
    Editorial: ulcer-related vs non-ulcer-nonvariceal upper gastrointestinal bleeding-which has worse outcomes?
    Aliment Pharmacol Ther. 2019;49:818-819.
    PubMed     Text format    
    
    
    February 2019
15. DONG R, Xu X, Yu L, Ding H, et al
    Randomised clinical trial: gabapentin vs baclofen in the treatment of suspected refractory gastro-oesophageal reflux-induced chronic cough.
    Aliment Pharmacol Ther. 2019 Feb 10. doi: 10.1111/apt.15169.
    PubMed     Text format     Abstract available
    
    
    January 2019
16. SEY MSL, Mohammed SB, Brahmania M, Singh S, et al
    Comparative outcomes in patients with ulcer- vs non-ulcer-related acute upper gastrointestinal bleeding in the United Kingdom: a nationwide cohort of 4478 patients.
    Aliment Pharmacol Ther. 2019 Jan 9. doi: 10.1111/apt.15092.
    PubMed     Text format     Abstract available
    
    
    
17. OSHIMA T, Arai E, Taki M, Kondo T, et al
    Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis.
    Aliment Pharmacol Ther. 2019;49:140-146.
    PubMed     Text format     Abstract available
    
    
    November 2018
18. BONDERUP OK
    Letter: the association between the use of different proton pump inhibitors and microscopic colitis should be re-evaluated-author's reply.
    Aliment Pharmacol Ther. 2018;48:1036.
    PubMed     Text format    
    
    
    
19. TAO P, Wang S
    Letter: the association between the use of different proton pump inhibitors and microscopic colitis should be re-evaluated.
    Aliment Pharmacol Ther. 2018;48:1035.
    PubMed     Text format    
    
    
    
20. 
    Retraction: Randomised clinical trial: The clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China by J.
    Aliment Pharmacol Ther. 2018;48:1039.
    PubMed     Text format     Abstract available
    
    
    
21. PONZETTO A, Figura N
    Letter: proton pump inhibitors and the risk of hepatocellular carcinoma.
    Aliment Pharmacol Ther. 2018;48:1164-1165.
    PubMed     Text format    
    
    
    
22. SHAO YJ, Wu SY
    Letter: association between proton pump inhibitors and the risk of hepatocellular carcinoma-authors' reply.
    Aliment Pharmacol Ther. 2018;48:1165-1166.
    PubMed     Text format    
    
    
    October 2018
23. RIBOLSI M, Cicala M, Zentilin P, Neri M, et al
    Prevalence and clinical characteristics of refractoriness to optimal proton pump inhibitor therapy in non-erosive reflux disease.
    Aliment Pharmacol Ther. 2018 Oct 7. doi: 10.1111/apt.14986.
    PubMed     Text format     Abstract available
    
    
    
24. ZHAO J, Hua L, Li N, An R, et al
    Letter: proton pump inhibitors use and risk of hepatocellular carcinoma: A meta-analysis of observational studies.
    Aliment Pharmacol Ther. 2018;48:886-888.
    PubMed     Text format    
    
    
    
25. KROL R, van Oijen MGH
    Editorial: proton pump inhibitors (PPIs) and microscopic colitis.
    Aliment Pharmacol Ther. 2018;48:880-881.
    PubMed     Text format    
    
    
    September 2018
26. BATCHELOR R, Kumar R, Gilmartin-Thomas JFM, Hopper I, et al
    Systematic review with meta-analysis: risk of adverse cardiovascular events with proton pump inhibitors independent of clopidogrel.
    Aliment Pharmacol Ther. 2018 Sep 4. doi: 10.1111/apt.14955.
    PubMed     Text format     Abstract available
    
    
    
27. SHAO YJ, Wu SY
    Letter: cohort study examining the association between proton pump inhibitors therapy and risk of hepatocellular carcinoma in Taiwan-authors' reply.
    Aliment Pharmacol Ther. 2018;48:690-691.
    PubMed     Text format    
    
    
    
28. LIAO KF, Lai HC, Lin CL, Lai SW, et al
    Letter: cohort study examining the association between proton pump inhibitor therapy and risk of hepatocellular carcinoma in Taiwan.
    Aliment Pharmacol Ther. 2018;48:689-690.
    PubMed     Text format    
    
    
    August 2018
29. WALDUM HL
    Editorial: proton pump inhibitors (PPIs) and primary liver cancer.
    Aliment Pharmacol Ther. 2018;48:380-381.
    PubMed     Text format    
    
    
    July 2018
30. BONDERUP OK, Nielsen GL, Dall M, Pottegard A, et al
    Significant association between the use of different proton pump inhibitors and microscopic colitis: a nationwide Danish case-control study.
    Aliment Pharmacol Ther. 2018 Jul 23. doi: 10.1111/apt.14916.
    PubMed     Text format     Abstract available
    
    
    
31. GATTA L, Scarpignato C
    Editorial: Helicobacter pylori resistance and sequential therapy-authors' reply.
    Aliment Pharmacol Ther. 2018;48:96-97.
    PubMed     Text format    
    
    
    
32. SIDDIQUE O, Moss SF
    Editorial: Helicobacter pylori resistance and sequential therapy.
    Aliment Pharmacol Ther. 2018;48:95-96.
    PubMed     Text format    
    
    
    June 2018
33. SHAO YJ, Chan TS, Tsai K, Wu SY, et al
    Association between proton pump inhibitors and the risk of hepatocellular carcinoma.
    Aliment Pharmacol Ther. 2018 Jun 13. doi: 10.1111/apt.14835.
    PubMed     Text format     Abstract available
    
    
    
34. ZHAO J, Wang JM, Zhang XW, An R, et al
    Letter: proton pump inhibitor use and risk of fracture.
    Aliment Pharmacol Ther. 2018;47:1570-1571.
    PubMed     Text format    
    
    
    
35. SUGIYAMA T
    Letter: association between proton pump inhibitor use and fracture risk - causality or confounding?
    Aliment Pharmacol Ther. 2018;47:1569-1570.
    PubMed     Text format    
    
    
    May 2018
36. TRAN KT, McMenamin UC, Hicks B, Murchie P, et al
    Proton pump inhibitor and histamine-2 receptor antagonist use and risk of liver cancer in two population-based studies.
    Aliment Pharmacol Ther. 2018 May 9. doi: 10.1111/apt.14796.
    PubMed     Text format     Abstract available
    
    
    
37. TSIPOTIS E, Leontiadis GI
    Editorial: the prevalence of Helicobacter pylori infection worldwide-knowns and unknowns.
    Aliment Pharmacol Ther. 2018;47:1330-1331.
    PubMed     Text format    
    
    
    
38. ZAMANI M, Derakhshan MH, Zamani V, Shokri-Shirvani J, et al
    Editorial: the prevalence of Helicobacter pylori infection worldwide-knowns and unknowns. Authors' reply.
    Aliment Pharmacol Ther. 2018;47:1331-1332.
    PubMed     Text format    
    
    
    
39. TRIGGS JR, Kahrilas PJ
    Editorial: symptom association probability during reflux testing-what is the gain?
    Aliment Pharmacol Ther. 2018;47:1317-1318.
    PubMed     Text format    
    
    
    April 2018
40. VENERITO M, Schneider C, Costanzo R, Breja R, et al
    Contribution of Helicobacter pylori infection to the risk of peptic ulcer bleeding in patients on nonsteroidal anti-inflammatory drugs, antiplatelet agents, anticoagulants, corticosteroids and selective serotonin reuptake inhibitors.
    Aliment Pharmacol Ther. 2018 Apr 14. doi: 10.1111/apt.14652.
    PubMed     Text format     Abstract available
    
    
    
41. TABIBIAN JH, Lindor KD
    Editorial: is proton pump inhibitor use associated with worse outcomes in patients with liver abscesses?
    Aliment Pharmacol Ther. 2018;47:1226-1227.
    PubMed     Text format    
    
    
    
42. BETTINGER D, Thimme R, Boettler T
    Editorial: is proton pump inhibitor use associated with worse outcomes in patients with liver abscesses? Authors' reply.
    Aliment Pharmacol Ther. 2018;47:1228-1229.
    PubMed     Text format    
    
    
    March 2018
43. GATTA L, Scarpignato C, Fiorini G, Belsey J, et al
    Impact of primary antibiotic resistance on the effectiveness of sequential therapy for Helicobacter pylori infection: lessons from a 5-year study on a large number of strains.
    Aliment Pharmacol Ther. 2018 Mar 14. doi: 10.1111/apt.14597.
    PubMed     Text format     Abstract available
    
    
    
44. TORVINEN-KIISKINEN S, Tolppanen AM, Koponen M, Tanskanen A, et al
    Proton pump inhibitor use and risk of hip fractures among community-dwelling persons with Alzheimer's disease-a nested case-control study.
    Aliment Pharmacol Ther. 2018 Mar 6. doi: 10.1111/apt.14589.
    PubMed     Text format     Abstract available
    
    
    February 2018
45. ZAMANI M, Ebrahimtabar F, Zamani V, Miller WH, et al
    Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection.
    Aliment Pharmacol Ther. 2018 Feb 12. doi: 10.1111/apt.14561.
    PubMed     Text format     Abstract available
    
    
    
46. SUGIYAMA T
    Letter: proton pump inhibitor use and fracture risk.
    Aliment Pharmacol Ther. 2018;47:449-450.
    PubMed     Text format    
    
    
    January 2018
47. BETTINGER D, Martin D, Rieg S, Schultheiss M, et al
    Treatment with proton pump inhibitors is associated with increased mortality in patients with pyogenic liver abscess.
    Aliment Pharmacol Ther. 2018 Jan 12. doi: 10.1111/apt.14512.
    PubMed     Text format     Abstract available
    
    
    
48. HU Y, Wan JH, Li XY, Zhu Y, et al
    Editorial: recurrence of Helicobacter pylori infection-still the same after all these years... Authors' reply.
    Aliment Pharmacol Ther. 2018;47:132-133.
    PubMed     Text format    
    
    
    
49. SHAH E, Chey WD
    Editorial: recurrence of Helicobacter pylori infection-still the same after all these years....
    Aliment Pharmacol Ther. 2018;47:131-132.
    PubMed     Text format    
    
    
    
50. MACNAUGHTAN J, Jalan R
    Editorial: proton pump inhibitor therapy and liver disease progression-more cause for concern?
    Aliment Pharmacol Ther. 2018;47:304-305.
    PubMed     Text format    
    
    
    December 2017
51. SONG M, Camargo MC, Weinstein SJ, Murphy G, et al
    Serum pepsinogen 1 and anti-Helicobacter pylori IgG antibodies as predictors of gastric cancer risk in Finnish males.
    Aliment Pharmacol Ther. 2017 Dec 15. doi: 10.1111/apt.14471.
    PubMed     Text format     Abstract available
    
    
    November 2017
52. BROERS C, Tack J, Pauwels A
    Review article: gastro-oesophageal reflux disease in asthma and chronic obstructive pulmonary disease.
    Aliment Pharmacol Ther. 2017 Nov 29. doi: 10.1111/apt.14416.
    PubMed     Text format     Abstract available
    
    
    
53. HWANG YJ, Kim N, Lee HS, Lee JB, et al
    Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication - a prospective study for up to 10 years.
    Aliment Pharmacol Ther. 2017 Nov 29. doi: 10.1111/apt.14424.
    PubMed     Text format     Abstract available
    
    
    
54. LI DK, Yan P, Abou-Samra AB, Chung RT, et al
    Proton pump inhibitors are associated with accelerated development of cirrhosis, hepatic decompensation and hepatocellular carcinoma in noncirrhotic patients with chronic hepatitis C infection: results from ERCHIVES.
    Aliment Pharmacol Ther. 2017 Nov 3. doi: 10.1111/apt.14391.
    PubMed     Text format     Abstract available
    
    
    September 2017
55. HU Y, Wan JH, Li XY, Zhu Y, et al
    Systematic review with meta-analysis: the global recurrence rate of Helicobacter pylori.
    Aliment Pharmacol Ther. 2017 Sep 11. doi: 10.1111/apt.14319.
    PubMed     Text format     Abstract available
    
    
    
56. FRASER AG
    Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori.
    Aliment Pharmacol Ther. 2017;46:550-551.
    PubMed     Text format    
    
    
    
57. JUNG YS, Kim EH, Park CH
    Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori-authors' reply.
    Aliment Pharmacol Ther. 2017;46:551-552.
    PubMed     Text format    
    
    
    
58. KAGAWA T, Iwamuro M, Inaba T
    Letter: a potassium-competitive acid blocker vs a proton pump inhibitor for healing endoscopic submucosal dissection-induced artificial ulcers after treatment of gastric neoplasms-authors' reply.
    Aliment Pharmacol Ther. 2017;46:566.
    PubMed     Text format    
    
    
    
59. BAN H, Sugimoto M, Otsuka T, Murata M, et al
    Letter: a potassium-competitive acid blocker vs a proton pump inhibitor for healing endoscopic submucosal dissection-induced artificial ulcers after treatment of gastric neoplasms.
    Aliment Pharmacol Ther. 2017;46:564-565.
    PubMed     Text format    
    
    
    
60. KOUNTOURAS J, Polyzos SA, Katsinelos P, Doulberis M, et al
    Letter: Helicobacter pylori in lean and obese patients with non-alcoholic fatty liver disease.
    Aliment Pharmacol Ther. 2017;46:637-638.
    PubMed     Text format    
    
    
    August 2017
61. KWON Y, Jeon S, Nam S, Shin I, et al
    Helicobacter pylori infection and serum level of pepsinogen are associated with the risk of metachronous gastric neoplasm after endoscopic resection.
    Aliment Pharmacol Ther. 2017 Aug 11. doi: 10.1111/apt.14263.
    PubMed     Text format     Abstract available
    
    
    
62. ZAGARI RM, Rabitti S, Greenwood DC, Eusebi LH, et al
    Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis.
    Aliment Pharmacol Ther. 2017 Aug 7. doi: 10.1111/apt.14248.
    PubMed     Text format     Abstract available
    
    
    
63. SAFIRI S, Ayubi E
    Letter: functional dyspepsia is associated with duodenal eosinophilia in an Australian paediatric cohort-methodological issues to avoid misinterpretation.
    Aliment Pharmacol Ther. 2017;46:387.
    PubMed     Text format    
    
    
    June 2017
64. CHEN WC, Lin KH, Huang YT, Tsai TJ, et al
    The risk of lower gastrointestinal bleeding in low-dose aspirin users.
    Aliment Pharmacol Ther. 2017;45:1542-1550.
    PubMed     Text format     Abstract available
    
    
    May 2017
65. GENTA RM, Turner KO, Sonnenberg A
    Demographic and socioeconomic influences on Helicobacter pylori gastritis and its pre-neoplastic lesions amongst US residents.
    Aliment Pharmacol Ther. 2017 May 25. doi: 10.1111/apt.14162.
    PubMed     Text format     Abstract available
    
    
    
66. LAURSEN SB, Leontiadis GI, Stanley AJ, Hallas J, et al
    The use of selective serotonin receptor inhibitors (SSRIs) is not associated with increased risk of endoscopy-refractory bleeding, rebleeding or mortality in peptic ulcer bleeding.
    Aliment Pharmacol Ther. 2017 May 23. doi: 10.1111/apt.14153.
    PubMed     Text format     Abstract available
    
    
    
67. YI S, Lee H, Jang SB, Byun HM, et al
    A novel K+ competitive acid blocker, YH4808, sustains inhibition of gastric acid secretion with a faster onset than esomeprazole: randomised clinical study in healthy volunteers.
    Aliment Pharmacol Ther. 2017 May 21. doi: 10.1111/apt.14148.
    PubMed     Text format     Abstract available
    
    
    
68. JUNG YS, Kim EH, Park CH
    Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication.
    Aliment Pharmacol Ther. 2017 May 12. doi: 10.1111/apt.14130.
    PubMed     Text format     Abstract available
    
    
    
69. COYLE C, Crawford G, Wilkinson J, Thomas SJ, et al
    Randomised clinical trial: addition of alginate-antacid (Gaviscon Double Action) to proton pump inhibitor therapy in patients with breakthrough symptoms.
    Aliment Pharmacol Ther. 2017 May 2. doi: 10.1111/apt.14064.
    PubMed     Text format     Abstract available
    
    
    April 2017
70. SUGIMOTO M, Ban H, Hira D, Kamiya T, et al
    Letter: CYP3A4/5 genotype status and outcome of vonoprazan-containing Helicobacter pylori eradication therapy in Japan.
    Aliment Pharmacol Ther. 2017;45:1009-1010.
    PubMed     Text format    
    
    
    March 2017
71. MASTRACCI L, Fiocca R, Engstrom C, Attwood S, et al
    The dynamics of the oesophageal squamous epithelium 'normalisation' process in patients with gastro-oesophageal reflux disease treated with long-term acid suppression or anti-reflux surgery.
    Aliment Pharmacol Ther. 2017 Mar 21. doi: 10.1111/apt.14038.
    PubMed     Text format     Abstract available
    
    
    
72. VAKIL N, Vieth M, Wernersson B, Wissmar J, et al
    Diagnosis of gastro-oesophageal reflux disease is enhanced by adding oesophageal histology and excluding epigastric pain.
    Aliment Pharmacol Ther. 2017 Mar 20. doi: 10.1111/apt.14028.
    PubMed     Text format     Abstract available
    
    
    
73. TALEBI BEZMIN ABADI A
    Letter: more studies are needed to elucidate any association between Helicobacter pylori infection and Barrett's metaplasia.
    Aliment Pharmacol Ther. 2017;45:764-765.
    PubMed     Text format    
    
    
    February 2017
74. SHAW J, Bajaj JS
    Editorial: should the inappropriate use of proton pump inhibitors be a quality assurance issue in cirrhotic patients?
    Aliment Pharmacol Ther. 2017;45:476-477.
    PubMed     Text format    
    
    
    
75. CHEN PY, Wu MS, Liou JM
    Letter: levofloxacin resistance - a challenge for treatment of Helicobacter pylori infection. Authors' reply.
    Aliment Pharmacol Ther. 2017;45:573.
    PubMed     Text format    
    
    
    
76. ZAMANI M, Shokri-Shirvani J, Zamani V
    Letter: levofloxacin resistance - a challenge for the treatment of Helicobacter pylori infection.
    Aliment Pharmacol Ther. 2017;45:572-573.
    PubMed     Text format    
    
    
    
77. AHN JS, Sinn DH, Son HJ, Gwak GY, et al
    Letter: Helicobacter pylori-related non-alcoholic fatty liver disease with concomitant metabolic syndrome as risk factor for colorectal neoplasia - authors' reply.
    Aliment Pharmacol Ther. 2017;45:577-578.
    PubMed     Text format    
    
    
    
78. KOUNTOURAS J, Polyzos SA, Kapetanakis N, Katsinelos P, et al
    Letter: Helicobacter pylori-related non-alcoholic fatty liver disease with concomitant metabolic syndrome as risk factor for colorectal neoplasia.
    Aliment Pharmacol Ther. 2017;45:576-577.
    PubMed     Text format    
    
    
    January 2017
79. SCHIAVON LL, Silva TE, Fischer J, Narciso-Schiavon JL, et al
    Letter: proton pump inhibitors and prognosis of cirrhosis - searching for the balance point.
    Aliment Pharmacol Ther. 2017;45:378-379.
    PubMed     Text format    
    
    
    November 2016
80. MIWA H, Uedo N, Watari J, Mori Y, et al
    Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials.
    Aliment Pharmacol Ther. 2016 Nov 27. doi: 10.1111/apt.13876.
    PubMed     Text format     Abstract available
    
    
    
81. SONNENBERG A, Turner KO, Spechler SJ, Genta RM, et al
    The influence of Helicobacter pylori on the ethnic distribution of Barrett's metaplasia.
    Aliment Pharmacol Ther. 2016 Nov 9. doi: 10.1111/apt.13854.
    PubMed     Text format     Abstract available
    
    
    October 2016
82. COLE HL, Pennycook S, Hayes PC
    The impact of proton pump inhibitor therapy on patients with liver disease.
    Aliment Pharmacol Ther. 2016 Oct 23. doi: 10.1111/apt.13827.
    PubMed     Text format     Abstract available
    
    
    
83. SAVARINO E, Girardin G, Della Coletta M, Ottonello A, et al
    Letter: proton pump inhibitor-responsive oesophageal eosinophilia - more than just gastro-oesophageal reflux disease. Authors' reply.
    Aliment Pharmacol Ther. 2016;44:912-3.
    PubMed     Text format    
    
    
    
84. MOLINA-INFANTE J, Katzka DA, Spechler SJ
    Letter: proton pump inhibitor-responsive oesophageal eosinophilia - more than just gastro-oesophageal reflux disease.
    Aliment Pharmacol Ther. 2016;44:911-2.
    PubMed     Text format    
    
    
    September 2016
85. MARTIN FC, Chenevix-Trench G, Yeomans ND
    Systematic review with meta-analysis: fundic gland polyps and proton pump inhibitors.
    Aliment Pharmacol Ther. 2016 Sep 15. doi: 10.1111/apt.13800.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Peptic Ulcer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: